v3.3.1.900
Earnings Per Share (Details) - $ / shares
shares in Millions
 3 Months Ended 12 Months Ended
Jan. 03, 2016
 [1]
Sep. 27, 2015
 [2]
Jun. 28, 2015
 [3]
Mar. 29, 2015
 [4]
Dec. 28, 2014
 [5]
Sep. 28, 2014
 [6]
Jun. 29, 2014
 [7]
Mar. 30, 2014
 [8]
Jan. 03, 2016
Dec. 28, 2014
Dec. 29, 2013
Reconciliation of basic net earnings per share to diluted net earnings per share                      
Basic net earnings per share $ 1.16 $ 1.21 $ 1.63 $ 1.55 $ 0.90 $ 1.69 $ 1.53 $ 1.67 $ 5.56 $ 5.80 $ 4.92
Average shares outstanding — basic                 2,771.8 2,815.2 2,809.2
Potential shares exercisable under stock option plans                 141.5 142.6 148.5
Less: shares repurchased under treasury stock method                 (102.6) (96.5) (103.3)
Convertible debt shares                 2.2 2.6 3.0
Accelerated share repurchase program                 0.0 0.0 19.6
Average shares outstanding - diluted                 2,812.9 2,863.9 2,877.0
Diluted net earnings per share $ 1.15 $ 1.20 $ 1.61 $ 1.53 $ 0.89 $ 1.66 $ 1.51 $ 1.64 $ 5.48 $ 5.70 $ 4.81
[1] The fourth quarter of 2015 includes a restructuring charge of $415 million after-tax ($590 million before-tax), $156 million after-tax ($214 million before-tax) from impairment of in-process research and development and Synthes integration costs of $59 million after-tax ($83 million before-tax). Additionally, the fourth quarter of 2015 includes the gain on the Cordis divestiture.
[2] The third quarter of 2015 includes net litigation expense of $348 million after-tax ($409 million before-tax).
[3] The second quarter of 2015 includes net litigation expense of $23 million after-tax ($134 million before-tax).
[4] The first quarter of 2015 includes a net litigation gain of $253 million after-tax ($402 million before-tax) and $122 million after-tax ($139 million before-tax) for costs associated with the DePuy ASRTM Hip program.
[5] The fourth quarter of 2014 includes litigation expense, primarily related to product liability and patent litigation of $652 million after-tax ($692 million before-tax), Synthes integration costs of $237 million after-tax ($325 million before-tax) and $115 million after-tax ($156 million before-tax) from impairment of in-process research and development.
[6] The third quarter of 2014 includes an additional year of the Branded Prescription Drug Fee of $220 million after and before tax, litigation expense of $231 million after-tax ($285 million before-tax), Synthes integration costs of $130 million after-tax ($167 million before-tax) and $111 million after-tax ($126 million before-tax) for costs associated with the DePuy ASRTM Hip program. Additionally, the fiscal third quarter of 2014 includes a net gain of $1.1 billion after-tax ($1.9 billion before-tax) for the divestiture of the Ortho-Clinical Diagnostics business.
[7] The second quarter of 2014 includes litigation expense of $342 million after-tax ($276 million before-tax) and Synthes integration costs of $104 million after-tax ($144 million before-tax).
[8] The first quarter of 2014 includes Synthes integration costs of $84 million after-tax ($118 million before-tax) and a $398 million tax benefit associated with Conor Medsystems.